Journal: mAbs

Article Title: Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy

doi: 10.1080/19420862.2026.2639673

Figure Lengend Snippet: SPR competition assays of three antibodies and ST2. IL-33 was immobilized on a CM5 sensor chip. Injections were performed in two steps: first, protein 1 was injected for 150 s, followed by a mixture of protein 1 and protein 2 for 150 s. From left to right: competition profiles for itepekimab + ST2, etokimab + ST2, and tozorakimab + ST2, ST2 = 200 nM，Abs = 100 nM.

Article Snippet: AD Atopic dermatitis AHR Airway hyperresponsiveness AP-1 Activator protein-1 BSA Bovine serum albumin CDR Complementarity-determining region COPD Chronic obstructive pulmonary disease cryo-EM Cryo-electron microscopy ELISA Enzyme-linked immunosorbent assay FC Fragment crystallizable Fab Fragment antigen-binding FR Framework region GST Glutathione S-transferase HEK Human embryonic kidney HBS HEPES-buffered saline HRP Horseradish peroxidase IBD Inflammatory bowel disease IC50 Half-maximal inhibitory concentration IC90 90% inhibitory concentration IL Interleukin IL-1RAcP Interleukin-1 receptor accessory protein IPTG Isopropyl β-D-1-thiogalactopyranoside NF-κB Nuclear factor kappa B PBS Phosphate-buffered saline PBMC Peripheral blood mononuclear cell PDB Protein Data Bank PEI Polyethylenimine RU Response unit SEAP Secreted embryonic alkaline phosphatase SPR Surface plasmon resonance ST2 Suppression of tumorigenicity 2 (IL1RL1)

Techniques: Injection